A Lethal Mouse Model for Evaluating Prophylactics and Therapeutics against Monkeypox Virus

Running title: Monkeypox infection of mice

Jennifer Stabenow¹,², R. Mark Buller²*, Jill Schriewer², Cheri West³, John E. Sagartz⁴ and Scott Parker²

²Department of Molecular Microbiology and Immunology, and ³Department of Comparative Medicine
Saint Louis University Medical School
1100 S. Grand Blvd.
St Louis
MO, 63104
USA

⁴Seventh Wave Laboratories, LLC
743 Sprint 40 Park Drive
Suite 209
Chesterfield,
MO, 63005
USA

¹Current Address: University of Tennessee Health Science Center. Regional Biocontainment Laboratory. 858 Madison Ave. Memphis, TN, 38163 USA

*Corresponding author. Tel 314 977 8870. Fax 314 977 871. mark.buller@gmail.com

Abstract word count: 186
Text word count: 5605
Monkeypox virus is an orthopoxvirus closely related to variola, the etiological agent of smallpox. In humans, MPXV causes a disease similar to smallpox and is considered to be an emerging infectious disease. Moreover, the use of MPXV for bioterroristic/biowarfare activities is of significant concern. Available small animal models of human monkeypox have been restricted to mammals with poorly defined biologies that also have limited reagent availability. We have established a murine MPXV model utilising the STAT1 deficient C57BL/6 mouse. Here we report that a relatively low dose intranasal infection induces 100% mortality in the stat1−/− model by day 9 post infection with high infectious titres in the livers, spleens and lungs of moribund animals. Vaccination with MVA followed by a booster vaccination is sufficient to protect against an intranasal MPXV challenge and induces a more robust immune response compared to a single vaccination. Furthermore, antiviral treatment with CMX001 (HDP-cidofovir) and ST-246 protect when administered as a regimen initiated on the day of infection. Thus, the stat1−/− model provides a lethal murine platform for evaluating therapeutics and for investigating the immunological and pathological responses to MPXV infection.
Introduction

During the early smallpox-free epoch the orthopoxviruses were of minor bio-terroristic concern due to the largely vaccinated population; however, this has changed with the increased risk of bio-terrorism and variola virus (VARV) and monkeypox virus (MPXV) are considered to have significant potential to become bioterror agents \(^{36,37}\). VARV, the etiological agent of smallpox, is officially stored at two WHO secure laboratories in the United States and Russia; however, there is concern that covert stocks exist. Furthermore, we are currently faced with the possibility of intentional release of wild-type, or genetically modified, VARV. Of most concern would be viruses encoding human IL-4 which could significantly increase virulence as demonstrated with the mousepox/ectromelia virus (ECTV) model \(^{18}\). As a result of the cessation of routine vaccination, and the high number of individuals that are contraindicated for vaccination, the human population lacks solid “herd immunity” to naturally circulating orthopoxviruses. One such virus that is of particular concern is MPXV, due to its ability to infect humans, its mortality rate of approximately 10% (depending on the strain), its propensity to infect a large number of species, its apparent increasing transmissibility in the human population, and its reportedly expanding host range \(^{36}\). One such example of increasing host range was observed during 2003 in the United States where imported African rodents transmitted MPXV to native Prairie Dogs which acted as an ‘amplification reservoir’ that allowed for the transmission of MPXV to humans \(^{14}\).

To date, MPXV animal models for efficacy testing of prophylactics and therapeutics have been restricted to non-human primates and non-murine small animal models, such as: the thirteen lined ground squirrel \((Spermophilus tridecemlineatus)\) \(^{49,55}\), the black tailed prairie dog \((Cynomys ludovicianus)\) \(^{14,17,22,60}\) and the African
Because the ground squirrel and the prairie dog are difficult to propagate, have low fecundity rates and have complex husbandry requirements, they must be obtained from their natural habitat, and therefore have unknown health statuses. Conversely, the African dormouse has many characteristics similar to laboratory mice and can be easily propagated in a research vivarium. The disadvantage to this model is that there are few commercially available reagents for characterizing the animals’ response to infection, and their biology is poorly understood.

Suckling white mice have been shown to be highly susceptible to MPXV virus inoculations by various routes. Eight day old white mice developed disease and died following intraperitoneal or intranasal inoculations with 1.2X10^6 PFU. Injection into the footpad also induced severe disease and death following 6X10^2 PFU inoculations. Disease symptoms included flabbiness, loss of appetite and, following footpad infections, edema of the foot. Similar symptoms were observed following inoculation by the oral route which induced 40% lethality. Intradermal inoculations with MPXV resulted in 50% death. The intranasal route of infection was determined to induce the highest level of lethality, causing 100% death in mice as old as 15 days, compared to only 14% and 60% lethality in 12 day old mice infected orally or via the footpad, respectively. Recently, Osorio et al showed that 4 week old SCID-BALB/c mice are susceptible to 10^5 PFU intraperitoneal (IP) MPXV inoculations which results in a mean day of death of 9 days post infection. Unfortunately the IP route of infection does not model the natural transmission route of MPXV.

Several factors make young (<15 days old) white mice a poor choice for studying MPXV. Firstly, mice do not become fully immunocompetent until...
approximately 4-5 weeks old; therefore the opportunity to study the immune response to infection is hampered. Moreover, immuno-immature animals cannot be used as models to study MPXV infections in immuno-competent humans. Secondly, a functioning immune system works in synergy with antiviral therapies to provide protection against viral challenge; thus, antiviral efficacy cannot be properly evaluated. Thirdly, the relatively short susceptible time-window of birth to 15 days old makes large-scale experiments impractical. Fourthly, young immuno-immature mice cannot be used to study vaccination efficacy. To this end, we sought to identify adult mice that are susceptible to lethal MPXV challenges and can be used for antiviral and vaccination efficacy studies.

In the present study we found that most common strains of adult immunocompetent laboratory mice are resistant to MPXV. We also found that type 1 and type 2 interferon (IFN) receptor null mice were resistant. Because strains lacking STAT1, a key protein involved in type 1 and 2 IFN signalling networks, have been shown to be sensitive to a wide-number of viral and bacterial infections \cite{13,15,30,46,52-54}, we evaluated their sensitivities to MPXV challenges. We found that C57BL/6 mice lacking stat1 (C57BL/6 stat1^{-/-}) were highly sensitive to MPXV and that 129 mice lacking stat1 were sensitive, but to a lesser degree than the C57BL/6 stat1^{-/-} animals. In this report, we show that the disease course in MPXV infected C57BL/6 stat1^{-/-} mice is similar to that observed in wild-type mice infected with ECTV, the etiological agent of mousepox \cite{11}. That is, weight-loss and death by day 10 post infection. Further, we reveal that antiviral therapy with CMX001 or ST-246 protects mice to a similar degree as vaccination with Dryvax\textsuperscript{TM} or MVA supporting the use of the C57BL/6 stat1^{-/-} as a model to evaluate orthopoxvirus prophylactics and therapeutics.
Materials and methods

Mice

The Institutional Animal Care and Use Committee at Saint Louis University School of Medicine approved all experimental protocols. C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD). SCID, DBA, A/Ncr, C3HeJ, IFNγR−/− and BALB/c were acquired from Jackson Laboratories (Bar Harbour, ME). IFN-α/βR−/− mice were provided by Dr. Lynda Morrison (Saint Louis University) who acquired them from Dr. Michel Aguet. The 129 stat1−/− mouse strain was acquired from Taconic (Hudson, NY), it was originally developed in the laboratory of Dr. Robert Schreiber at Washington University School of Medicine (St. Louis, MO). C57BL/6 mice carrying a stat1−/− mutation were provided by Dr. Michael Holtzman (Washington University School of Medicine) who acquired them from Dr. Joan Durbin (New York University School of Medicine, NY). It was noted during husbandry of the C57BL/6 stat1−/− mouse strain that with age (~12 months of age) this line showed a propensity to develop tumours of distinct lineages (data not shown).

All experimental and animal procedures were completed at BSL-3 or ABSL-3. A standard rodent diet (Teklad Global 18% Protein Rodent Diet) and water were provided ad libitum. Corn cob bedding was provided in each cage where no more than 4 animals were housed. All animals were acclimatised for at least 1 week prior to infection. Animals were 6-12 weeks in age and experiments consisted of a minimum of 5 animals per group (see legends for actual N values).

Speed congenic analysis (Washington University, St Louis, MO) was used to determine the genetic purity of our C57BL/6 stat1−/− breeding stock. Analysis revealed...
that stat1-/- mice were 89.5% homologous with wild-type alleles (consistent with approximately 8 out-crosses).

**Cells and virus**

The strain of MPXV used in these studies was MPXV-ZAI-79 which was originally isolated in 1979 from a fatal human monkeypox case in Zaire (now Democratic Republic of the Congo) 63. The ABSL-3 and BSL-3 rooms used for MPXV studies were registered with CDC under the Select Agent program (Saint Louis University's Select Agent Registration number is C20090519-0847).

BSC-1 cells were grown in Eagle's minimum essential medium (EMEM; Bio-Whittaker, Walkersville, MD) containing 10% foetal bovine sera (Hyclone, Logan, UT), 2 mM l-glutamine (GIBCO, Grand Island, NY), 100 U/ml of penicillin (GIBCO, Grand Island, NY), and 100 µg/ml of streptomycin (GIBCO, Grand Island, NY).

Virus plaque assays were carried out on BSC-1 cell monolayers as previously described 6. Virus was purified through a sucrose cushion as described elsewhere 27.

**Interferon gamma cytokine assay**

Antigen presenting cells were generated by infecting naïve splenocytes overnight at an MOI (multiplicity of infection) of 0 or 0.1. The cells were then irradiated at 2500 rads, labelled with CFSE (BD Biosciences) and co-cultured with responder populations overnight. Samples were incubated for 4-6 hours with Golgi Plug (BD Biosciences, washed with PBS-1% Foetal Clone II and stained for surface markers. The cells were fixed using Cytofix (BD Biosciences). For intracellular staining, the cells were washed twice in Permwash buffer (BD Biosciences) and incubated with
anti-IFN-γ antibody (clone XMG1.2). The cells were washed twice in Permwash buffer and analyzed on a BD LSRII flow cytometer.

Antiviral Compounds

CMX001, was a gift from Chimerix Inc., (Durham, NC). Solutions of CMX001 were prepared by dissolving the compound in normal saline to make a stock solution of 25 mg/ml, which was frozen at -20°C. The stock solution was diluted in normal saline to obtain working stocks.

ST-246 was a gift from SIGA Technologies (Corvallis, OR). The compound was prepared by adding 0.75% carboxyl methyl cellulose and 1% Tween (CMC) to make a final concentration of 10 mg/ml and was stored at 4°C on a stir plate. For CMX001 and ST-246, animals were dosed via gastric gavage beginning at T=0 approximately 4 hours p.i.

Vaccination

For Dryvax™ vaccinations, mice were vaccinated with 2.5 µl (which is the volume that fills the bifurcated needle) of PBS (without Ca²⁺ and Mg²⁺) containing approximately 2.5X10⁵ PFU Dryvax™ at the base of the tail with 15 punctures from a bifurcated needle (Precisions Medical Products, Inc., Denver, PA). For modified vaccinia Ankara (MVA) vaccinations, mice were intramuscularly injected with 50 µl (1x10⁸ TCID50 per 0.5 ml in TBS pH 7.7) of undiluted IMMAVUNE (MVA-BN, Bavarian Nordic, Germany).

Animal Infection
At day of infection (T=0), mice were anesthetized by intraperitoneal injection of 9 mg/ml ketamine HCl and 1 mg/ml xylazine at a ratio of 0.1 ml/10 g body weight. Intranasal infections with 5 µl/nare of MPXV-ZAI-79 were used to seed the upper respiratory tract as described previously.

Histopathology

Tissues from each of two C57BL/6 stat1−/− and 129 stat1−/− infected mice and each of one C57BL/6 stat1−/− and 129 stat1−/− uninfected control mice were collected for microscopic examination. The following tissues were collected in 10% neutral buffered formalin, fixed for 24 hours, and then transferred to 70% ethanol prior to trimming, processing, and embedding in paraffin: adrenal gland, aorta, bone marrow (femur), bone marrow (sternum), bone (femur), bone (sternum), brain, cecum, colon, duodenum, esophagus, eye, gall bladder, Harderian gland, heart, ileum, jejunum, kidney, larynx, liver, lung, lymph node (mandibular and mesenteric), mammary gland, nasal cavity, optic nerve, ovary, oviduct, pancreas, parathyroid, pituitary gland, rectum, salivary gland (mandibular), skeletal muscle, skin, spinal cord, spleen, stomach, thymus, thyroid, tongue, trachea, urinary bladder, uterus with cervix, and vagina. Paraffin sections were stained with hematoxylin and eosin and examined microscopically.

Plaque Neutralization Assay

Vaccinia virus (VACV, strain WR) was diluted in DMEM-2 to a concentration of approximately 1000 PFU/ml and aliquoted at 100 µl samples. The serum/virus mixture was incubated for 2 hours and then plated onto BSC-1 cells along with a virus-only control, a media-only control, and positive and negative controls of pooled
serum from A/Ncr mice percutaneously vaccinated with a 1:10 dilution of Dryvax™ and mock-vaccinated with PBS, respectively. The plate was incubated for 1 hour and then overlaid with overlay media. The plates were incubated for 48 hours at 37°C, stained with crystal violet and examined for plaque formation. The neutralization titre was taken as the reciprocal of the highest dilution of sera that caused a 50% reduction in the number of virus plaques as long as the titre is 2 fold over the sera from negative control mice.

ELISA assays

To determine the level of orthopoxvirus-specific antibodies in serum samples collected in the mouse study, a direct anti-vaccinia virus ELISA was performed using lysates from BSC-1 cells infected with VACV-WR. Clarified cell lysate was diluted in 50 mM carbonate-bicarbonate buffer (pH 9.6) at 1:2500 and used to coat 96-well microtiter ELISA plates at 4 °C overnight. Plates were blocked with blocking buffer (for 100 ml, 98 ml PBS-T [5 ml 10% Tween-20, 1 L PBS, pH 7.2] and 2 ml normal goat serum (Vector, Burlingame, CA)) at room temperature for 30 min, and serial dilutions of mouse sera were added to wells. Following incubation at room temperature for 1 h, wells were washed with PBS-T. Bound antibody was detected by using biotin-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA) at 1:2500 dilution followed by streptavidin-HRP (Invitrogen, Carlsbad, CA) at 1:4000 and orthophenylenediamine (0.4 mg/ml) in 50 mM citrate buffer (pH 5.0) as a chromogen. Optical density was measured at 490 nm.

Statistics
The Mann-Whitney test was used to compare the means of two groups of mice for percent weight changes and for comparison of the geometric means of the viral titres in tissue samples. Mortality rates were analyzed using Fisher’s exact test. T-tests were used in all other cases. P values below 0.05 were considered statistically significant.

Results

MPXV is not lethal to immunocompetent adult mice

MPXV is capable of infecting a broad number of species, including rodents, some monkeys, and humans. Adult mice have heretofore been reported as resistant. However, weanling mice (≤15 days old) have been reported to be susceptible to MPXV infections. Because MPXV and VARV are transmitted by the respiratory route and infection with these viruses are a major health concern, we investigated murine models of lethal infection following intranasal inoculation with MPXV. Table 1 summarises the response of a number of mouse strains to various doses of MPXV following intranasal and footpad inoculations. We found that the 129, C57BL/6, DBA, A/Ncr, C3HeJ, IFN-γR-/- and IFN-α/βR-/- mice were not susceptible to MPXV at doses from $10^2$ to $10^4$ PFU but all mice seroconverted. In contrast, the immunodeficient SCID strain was susceptible to an intranasal MPXV infection as were the C57BL/6 stat1-/- and 129 stat1-/- strains, which are characterised by their failure to respond to type 1 or 2 IFN induced STAT1 dependent signalling pathways (Table 1).

STAT1 null mice are susceptible to intranasal MPXV challenges.

To explore the response of stat1-/- mice to an intranasal MPXV challenge, we intranasally infected C57BL/6 stat1-/- mice with 4.7-4700 PFU and evaluated their
response to infection. At the 47 PFU dose, 25% of female mice died by day 21 p.i. (P=0.048 compared to NI), and 50% of male mice died by day 12 p.i. (P=0.17 compared to NI) (Figure 1 A and C). When infected with the highest dose of 4700 PFU, all animals died by 9 days p.i. (P=0.008 compared to NI). No animals died at the lowest dose of 4.7 PFU and any weight loss was insignificant (Figure 1 D). In the female mice, weight-loss was not observed at the 4.7 PFU dose, but it was significant at the 47 PFU dose in female mice (P=0.0071, 0.0012 and 0.0036 for days 9, 10 and 11 p.i., respectively, compared to uninfected) (Figure 1 B). We calculated the LD\textsubscript{50} values to be 213 and 47 PFU for females and males, respectively (Figure 1 A and C).

The failure of MPXV to lethally infect the C57BL/6 mice suggests that the susceptibility of the C57BL/6\textsuperscript{stat-1\textsuperscript{-/-}} mice is due to the \textit{stat1} mutation. To confirm that the observed phenotype was due the loss of \textit{stat1} and was not due to some other genetic polymorphism, we tested the susceptibility of the 129 \textit{stat1\textsuperscript{-/-}} mouse strain to an intranasal MPXV challenge. These mice were resistant to doses at, or below, 470 PFU (Table 1). At the highest dose of 4700 PFU, 20% of males died and 40% of females died by day 10 p.i., no wild-type 129 mice died (P=1.0 and 0.44 compared to NI, respectively) (data not shown). Because the \textit{stat1} mutant phenotype was more acute in the C57BL/6\textit{stat1\textsuperscript{-/-}} strain, compared to the 129 \textit{stat1\textsuperscript{-/-}} strain, we selected the C57BL/6 \textit{stat1\textsuperscript{-/-}} strain to further evaluate the pathogenicity of MPXV in a murine model.

We next determined the relative levels of virus replication. Female C57BL/6 \textit{stat1\textsuperscript{-/-}} mice were infected with 4600 PFU of MPXV and all died by day 9 p.i. Spleen, liver and lung samples from 8 days p.i. sacrificed animals were titred for infectious virus. Titrations revealed that the lung had the highest amount of infectious virus.
(1.7x10^5 PFU/g), followed by the spleen (1.7x10^4 PFU/g) and liver (1.8x10^2 PFU/g) (Figure 2). In 129 stat1^{+/−} animals, we detected no virus in the spleen, liver or lung at 8 days following an intranasal infection with the same virus dose (data not shown). This finding could be due to the 2-3 log higher LD_{50} in 129 stat-1^{+/−} mice that also have a longer disease course. Necropsies from day 8 p.i. infected C57BL/6 stat-1^{+/−} mice revealed that the spleens were enlarged approximately 4 fold and that the lungs were red and mottled. Animals were emaciated (as determined by low levels of abdominal fat) with distended abdomens and the entire GI tract, including the stomach, was filled with gas. Results of histopathologic examination of tissues from several sacrificed animals are described in Table 2.

Histopathology in C57BL/6 stat1^{+/−} and 129 stat1^{+/−} mice infected with MPXV

Histopathology results considered to be related to infection or potentially related to infection are summarized in Table 2. No specific microscopic lesion (NSML) changes were observed in C57BL/6 and 129 mice.

Microscopic changes associated with infection were generally comparable between the C57BL/6 stat1^{+/−} and 129 stat1^{+/−} (not shown) strains. In mice of each strain, minimal or mild acute leptomeningitis was observed in the cerebrum and optic nerve (Figure 3 A and B). In a single C57BL/6 stat1^{+/−} infected mouse, minimal acute ventriculitis was also observed within the brain.

Acute inflammation of the upper respiratory tract was observed in mice of both strains. Mild to severe exudation or fibrinopurulent rhinitis was observed in the nasal turbinates and nasal cavity of all infected mice (Figure 3 C and D). Mild subacute inflammation was present in the larynx of one C57BL/6 stat1^{+/−} infected mouse. In addition, in the lungs, a single C57BL/6 stat1^{+/−} infected mouse exhibited...
mild bronchointerstitial pneumonia and two mice exhibited hyperplasia of peribronchiolar lymphoid tissue.

In the liver and spleen of mice of both stat1Δ/Δ strains, extramedullary hematopoiesis was present (minimal to moderate in the liver, mild to severe in the spleen). In addition, mild or moderate bone marrow hyperplasia was present in all infected mice.

Lymphoid depletion (mild or severe) resulting in cortical atrophy was present in the thymus of C57BL/6 stat1Δ/Δ infected mice. In the mandibular lymph nodes, mild increased lymphocyte apoptosis was observed in C57BL/6 stat1Δ/Δ infected mice. Lymphoid apoptosis and/or depletion is a common non-specific finding in mice experiencing stress associated with debilitation from a variety of causes. In contrast, in one of the 129 infected mice, mild lymphoid hyperplasia was present (not shown). Two mice of each strain exhibited mild acute inflammation in the mandibular lymph node.

One C57BL/6 infected mouse exhibited moderate acute inflammation affecting both the ovary and oviduct. Although an unusual lesion, the singular incident of this finding makes it of uncertain relationship to infection.

MVA vaccination protects mice from a lethal MPXV challenge

To test the efficacy of the third generation MVA smallpox vaccine, groups of male and female C57BL/6 stat1Δ/Δ mice were vaccinated once with MVA via intramuscular injections at day -56 before MPXV infection, or twice via intramuscular injection at -56 days before infection with an MVA booster vaccination at day -28 before infection. All infected mice (day 0) vaccinated with placebo died by day 11 p.i. following a $4.2 \times 10^4$ PFU MPXV challenge (P=1.0) (Figure 4 A), but mice vaccinated
either once with MVA (d-56), or with MVA plus a booster vaccination (d-56, d-28), had similar survival levels of approximately 90% (P=0.0001 and 0.0001 compared to NI, respectively); however, mice that also received the booster vaccination at -28 days before infection experienced little weight-loss compared to mice vaccinated once, whom experienced significant weight-loss on day 6, 7 and 8 p.i (P= 0.0002, 0.0002 and 0.0004, respectively, compared to *stat1*<sup>−/−</sup> untreated)(Figure 4 A and B).

We next measured immunologic memory by intracellular IFN-γ staining in CD4<sup>+</sup> and CD8<sup>+</sup> cells from mice bled at 7 days before infection. We found that C57BL/6 and C57BL/6 *stat1*<sup>−/−</sup> mice that received a vaccination and a booster had significantly elevated amounts of intracellular IFN-γ in CD8<sup>+</sup> cells when exposed to viral antigen in vitro (C57BL/6: 1.0±0.29 and placebo 0.24±0.09, P=0.02. C57BL/6 *stat1*<sup>−/−</sup>: 1.15±0.4 and placebo 0.24±0.08, P=0.05)(Figure 4 C). Conversely, C57BL/6 *stat1*<sup>−/−</sup> animals that received only one vaccination failed to significantly increase their levels of intracellular IFN-γ in CD8<sup>+</sup> cells, compared to placebo controls (0.26±0.11 and placebo 0.23±0.09, P=0.84) (Figure 4 C). Thus, the absence of STAT1 had no effect on CD8<sup>+</sup> immunologic memory when mice were vaccinated and received a booster compared to wild-type mice. Levels of CD4<sup>+</sup> intracellular IFN-γ did not change significantly in any of the groups (Figure 4 D).

We also used ELISAs to check the antibody responses of mice following the primary vaccination and following the booster vaccination. To this end we bled mice at day -30 and day -7 before infection (Figure 4 E and F). C57BL/6 mice bled following the primary vaccination (day -30) had significantly increased antibody levels compared to unvaccinated C57BL/6 controls (0.34±0.04, 0.07±0.02, P=0.0006 at 1/200 dilution) and was similar to vaccinated C57BL/6 *stat1*<sup>−/−</sup> mice (Figure 4 E), which were generally higher than the antibody responses in placebo and untreated
C57BL/6 stat1−/− mice. At the -7 day time point, the C57BL/6 stat1−/− group that received the booster vaccination had significantly more antibodies (0.8±0.06) compared to both the C57BL/6 mice receiving booster vaccinations and to C57BL/6 stat1−/− mice (0.14±0.02, P=0.001) receiving only the primary vaccination (Figure 4 F); indicating a stronger antibody response in C57BL/6 stat1−/− mice following vaccination as compared to wild-type animals.

To measure the duration of the immune response in C57BL/6 stat1−/− mice vaccinated with MVA on d-56 and d-28, we bled mice at days 42, 72 and 105 and measured their serum antibody levels using ELISAs. We found no significant differences between the MVA vaccinated C57BL/6 stat1−/− mice and the wild-type C57BL/6 mice at any of the time points (data not shown). We also found that the antibody levels between day 42 and 105 significantly decreased in the C57BL/6 stat1−/− animals (0.95±0.11 at day 42, 0.49±0.14 at day 105, P=0.03) but did not significantly decrease in the C57BL/6 animals (0.76±0.11 at day 42, 0.82±0.1 at day 105, P=0.66).

Antiviral therapy protects C57BL/6 stat1−/− mice against a lethal MPXV challenge

Previously it has been shown that mice can be protected from lethal orthopoxvirus disease by the administration of antivirals, such as CMX001 and ST-246. To test whether C57BL/6 stat1−/− mice could be used to evaluate the efficacy of antivirals following MPXV challenges, we infected and treated C57BL/6 stat1−/− mice with CMX001, which is a DNA polymerase inhibitor, or with ST-246, which prevents viral release from infected cells. Following a 5000 PFU intranasal MPXV infection, groups of mice were treated with a 10 mg/kg dose of CMX001 on the day of infection, followed by every-other-day dosings with 2.5 mg/kg until day 14
All mice survived the MPXV challenge, had negligible weight loss, and seroconverted; however, when mice were re-challenged at day 38 p.i. we found that 20% died by 8 days post re-challenge (Figure 5 A). We also noted significant weight-loss in this group following re-challenge (Figure 5 B).

Mice treated with daily 100 mg/kg administrations of ST-246 for 10 days following infection also survived the initial infection and had negligible weight-loss (Figure 5 A and B); however, as with the CMX001 treatment group, 20% of these animals died by 15 days post re-challenge; unlike mice treated with CMX001, these mice experienced negligible weight-loss (Figure 5 B). All infected mice treated with either saline or CMC vehicles were dead by 9 days p.i.

Finally, we tested the neutralization values of antiviral treated mice. At 28 days p.i., we bled mice from groups treated with CMX001 or ST-246 and determined the 50% neutralization values. We found that mice treated with ST-246 had almost a double 50% neutralization value compared to mice treated with CMX001 (Figure 6); however, the increased titre of antibody did not correlate with increased survivability following rechallenge.

Discussion

In this study we found that tested immunocompetent mouse strains, as well as type 1 and type 2 IFN knockout strains, were resistant to MPXV infection. The immunocompromised SCID mouse is sensitive to an IN infection at <275 PFU and has also been shown to be sensitive to IP infections at $10^5$ PFU, but is limited by its lack of a fully functional immune system. We next evaluated STAT1 null mice, which are defective in their ability to initiate transcription of many type 1 and type 2 receptor IFN-stimulated genes (reviewed by). STAT1 null mice are highly sensitive
to a number of viral and bacterial infections, and have been used as the foundation for
developing several disease models, including: respiratory syncytial virus, influenza,
Listeria monocytogenes, Leishmania major, vesicular stomatitis virus, Sendai virus,
mouse hepatitis virus and others. The 129 stat1-/- mice revealed some sensitivity to intranasal MPXV infections
with doses higher than 470 PFU; however, the C57BL/6 stat1-/- strain was highly
sensitive to infection with LD90 values of 47 and 213 PFU for males and females
respectively. One possible explanation for the higher LD90 in the female could be
explained by their propensity to produce high levels of CD8+ intracellular IFN-γ (data
not shown). The differences in 129 stat1-/- and C57BL/6 stat1-/- strain sensitivities
indicate that background, strain, and potentially gender-specific alleles have an
important role in determining host susceptibility to MPXV infection. Also, the stat1
mutation is different between the mouse strains. The C57BL/6 stat1-/- strain produces
no detectable STAT1 antigen, whereas the 129 stat1-/- strain, which has a deletion in
the N-terminal domain, produces a limited amount of abnormal STAT1 that might
contribute to this strain's decreased sensitivity to MPXV. This is underpinned by
the finding that 129 stat1-/- mice had no detectable virus in their spleens, livers or
lungs at day 8 compared to C57BL/6 stat1-/- animals; however, some of the 129 stat1-/-
mice did become sick and die. It should be noted that the lack of detectable virus in
the tested tissue from the 129 stat1-/- mice could indicate that mortality was due to
pathology in other tissues, such as the brain - as leptomenigitis was reported in these
mice. Furthermore, the LD90 for this strain is likely 2-3 logs higher than that of the
C57BL/6 stat1-/- mice. That said, H and E data does indicate involvement of the
spleen and liver in the 129 stat1-/- animals (data not shown).
In contrast to our findings, cynomolgus monkeys infected with MPXV-ZAI-79 had papulovesicular lesions primarily in the lymph nodes and thymus. Gross lesions with a granulomatous appearance were demonstrated in the GI tract organs such as the stomach, small intestine and colon. Moreover, infected stat1−/− mice were associated with comparatively less severe histopathologic changes than those previously reported in dormice infected with MPXV-ZAI-79. In dormice, acute haemorrhage was present in numerous tissues, and significant hepatocellular necrosis was observed. While both species exhibited rhinitis, in dormice, nasal mucosal syncytial cell formation with intracytoplasmic viral inclusions was also observed. Leptomeningitis was not a feature of infection in dormice. In summary, the presence of the stat1 mutation changes a relatively low dose, intranasal infection from no apparent disease signs to one characterized by fulminant and lethal disease. It would be interesting to test under appropriate containment conditions adult stat1−/− mice for susceptibility to severe disease following VARV infection.

The sensitivity of stat1−/− mice to MPXV and myxoma virus infections suggests IFNs may be critical to recovery from poxvirus infections in general. Poxviruses, like most viruses, encode proteins that antagonize antiviral mechanisms mediated by IFN (reviewed by). VACV, an orthopoxvirus closely related to MPXV, encodes an inhibitor (H1) of phosphorylation of STAT-1 and STAT-2 following type 1 or type 2 IFN stimulation in vitro. VACV encodes IFN-binding proteins (B19 and B8) that block selected type 1 and 2 IFN-mediated induction of both STAT1-dependent and -independent genes, and are both essential for virulence. And finally, VACV encodes a phosphorylation resistant homologue of eIF2α (K3) and a double-stranded RNA binding protein (E3) that targets the PKR and 2′-5′OAS/RNaseL systems. MPXV, like other examined orthopoxviruses, encodes...
apparently intact orthologues of H1, B19, and B8; however, the K3 orthologue is fragmented and the amino terminal domain of the E3 orthologue is missing, which likely restricts function. The N-terminal domain of E3L shows sequence similarity with a group of host Z-DNA-binding proteins, ADAR-1 and Dlm, and has been shown to be important in spread of VACV in the mouse. We speculate that loss of the N-terminal domain of the MPXV E3 orthologue may contribute to the attenuated phenotype of MPXV in mice.

Treatment of C57BL/6 \textit{stat1}\(^{-/-}\) mice with CMX001 or ST-246 provided solid protection against MPXV challenges, with negligible weight-loss. The higher neutralization value from ST-246 treated and infected mice could be a result of an increasing amount of viral antigen which would likely be present because this drug has antiviral activity at the viral egress stage whereas CMX001 has activity at the DNA replication stage. Consideration should be given to the fact that MPXV is a complex virus that will induce the generation of a wide variety of antibodies and the ELISAs used in these experiments measure all anti-orthopoxvirus antibodies and not just those that are protective. Of some concern is the observation that some mice died following a re-challenge initiated several weeks after the cessation of drug treatment. This result suggests that surviving a drug-treated MPXV infection does not provide full immunity against subsequent MPXV challenge in the C57BL/6 \textit{stat1}\(^{-/-}\) mouse and therefore antibody titers alone do not directly correlate with protection. In contrast, C57BL/6 mice treated with CMX001 following an intranasal infection with ECTV are protected following re-challenge (data not shown). With regard to these data, consideration should be given to the quantity of animals being tested (N=5). That said, these data suggest that MPXV infected STAT1 deficient humans successfully treated with antiviral therapy may be susceptible to MPXV reinfection.
It is exciting to report in this study that we could successfully vaccinate stat1\(^{-/-}\) mice and protect them from a lethal MPXV challenge. A similar response has also been reported with rotavirus infections in stat1\(^{-/-}\) mice, which are resistant to subsequent challenge \(^{56}\). Vaccinating C57BL/6 stat1\(^{-/-}\) mice twice with MVA vaccine provided protection against subsequent MPXV challenges; however we found that a more robust response, as measured by ELISAs, was established following 2 inoculations with MVA - although protection was not improved as compared to a single vaccination. Indeed, following two vaccinations we found higher antibody titers in C57BL/6 stat1\(^{-/-}\) mice compared to wild-type C57BL/6 mice; however, this difference was not observed in a separate study where titers were measured days 42, 72 and 105 following vaccination. Although cell mediated and antibody response are complementary in controlling orthopoxvirus infections, certain studies have found that antibody is necessary and sufficient for recovery of immunized and infected mice from a subsequent lethal challenge with VACV or ECTV \(^{34}\) however, there is no data to our knowledge that relates amount of antibody to level of protection. From the literature, others have shown that robust cell-mediated and humoral responses can be generated in the absence of signalling pathways requiring STAT1 (reviewed by \(^{43}\)). Vaccinating C57BL/6 stat1\(^{-/-}\) mice with a single Dryvax\(^{\text{TM}}\) vaccination also provided partial protection (approximately 80%) against subsequent MPXV challenges, with negligible weight-loss (data not shown); that said, this vaccination did cause severe necrosis at the base of the tail where Dryvax\(^{\text{TM}}\) was administered, making it of limited utility, and suggesting that stat1\(^{-/-}\) mice are likely highly susceptible to non-vaccine strains of VACV (e.g Copenhagen or Western Reserve strains). These data suggest that humans with mutations in stat1 could be contraindicated to vaccination with
Dryvax\textsuperscript{TM} and ACAM2000, and following MVA vaccination may not receive the same level of protection as fully immunocompetent individuals.

Humans with heterozygous \textit{stat1} mutations have been shown to be unusually sensitive to mycobacterial but not viral infections; however, all patients recovered from infection\textsuperscript{8}. Homozygous mutations in \textit{stat1}, which completely abrogate STAT1 function, have been described in at least 3 infants whom developed disseminated BCG infections from which they subsequently recovered; however, all died at a later date from viral disease\textsuperscript{4,5,9}. Humans with the \textit{stat1} mutations have a differential susceptibility to severe virus disease. In one example a human carrying the homologous \textit{stat1} mutations could mount a protective immune response to clear the attenuated polio vaccine, a rhinovirus infection acquired after a bone marrow transplant, and a parainfluenza type II infection; however, the patient was not able to survive following an Epstein Barr virus infection\textsuperscript{5}. One reason for the differential response to viral infections of humans with the \textit{stat1} mutation could be due to the existence of IFN-induced STAT1 independent pathways, which have been studied in detail in mice.

Approximately 500 genes are regulated by the IFN-\textgamma/STAT1 pathway\textsuperscript{1}; however, it has been demonstrated that STAT1-independent responses to IFNs exist. For example, IFN-\textgamma treated, wild-type, bone marrow derived macrophages (BMMs) have expression changes in 216 transcripts, as detected by microarrays, compared to expression changes of 150 different transcripts in STAT1 null BMMs. Moreover, IFN-\textgamma dependent gene expression in serum-starved STAT1 null fibroblasts have been shown to control expression of several protein groups\textsuperscript{42,43}. The effective IFN stimulated STAT-1 independent responses may be dependent on the virus or stage of disease. We found that type 1 or type 2 IFN knockouts were resistant to MPXV
challenge, but stat1<sup>-/-</sup> mice were not. This therefore demonstrates that STAT1-independent pathways are not sufficient to protect C57BL/6 stat1<sup>+/+</sup> mice against relatively low MPXV challenges; although they could contribute to recovery of MPXV infected 129 stat1<sup>-/-</sup> mice which have a higher LD<sub>50</sub> value than C57BL/6 stat1<sup>+/+</sup> mice. This is not an unusual finding. Rothfuchs et al demonstrated that stat1<sup>-/-</sup> mice are more susceptible to Chlamydia pneumoniae infections than IFN-γ<sup>-/-</sup> or IFN-γR<sup>-/-</sup> strains. Similarly, mice infected with murine norovirus 1 are equally sensitive when carrying stat1<sup>-/-</sup>, or type 1 and 2 IFN receptor double knockouts suggesting that signalling through the STAT1 pathway is largely required for recovery from infection. In the case of dengue virus, the STAT1 pathway acts early and is required for controlling initial viral replication; however, the STAT1 independent pathway functions later and is required for complete viral clearance.

In summary, advantages to using a murine MPXV model for therapeutic development include: 1) biomarkers of disease progression have been established in the mousepox model and can be readily applied to the MPXV stat1<sup>+/+</sup> mouse model; 2) reagents are readily available and the biology and genetics of the mouse are well understood; 3) early in the drug development plan mice are invariably used to acquire efficacy, toxicity and pharmacokinetic/pharmacodynamic data; and 4) MPXV itself causes a natural disease in humans, unlike VACV and ECTV which are used in other mouse models.

In the ECTV/mousepox model, we and others have evaluated successful, delayed-dosings, with CMX001 and ST-246. Further evaluation of dosing regimens would be a logical next step to evaluate drug efficacy against MPXV in C57BL/6 stat1<sup>+/+</sup> mice.
Acknowledgments

This work was supported by NIAID grant NOI-AI-15436 and U54-AI-057169 from the NIAID to the Midwestern Regional Centre of Excellence for Biodefense and Emerging Infectious Diseases (MRCE). We wish to thank Mike Bray for critically reviewing this manuscript.


---

**Figure Legends**

**Figure 1**

Dose response to MPXV challenge in female and male C57Bl/6 *stat1<−/−* mice
Male and female mice were inoculated with 4.7-4700 PFU of MPXV and monitored for death (A and C) and weight-loss (B and D). The higher doses of 4700 and 470 PFU induced significant weight-loss from approximately 4 days, p.i. * indicates 1 death at day 21 (75% survival). N=5 mice per group.

**Figure 2**

Day 8 end-point tissue titres

Liver, spleen and lung titres from mice sacrificed on day 8 p.i. N=5 mice per group.

**Figure 3**

Histopathology (H and E) of the cerebrum, optic nerve, nasal turbinates and nasal cavity

(A) Ventral cerebrum and optic nerve from C57BL/6 stat1^{-/-} mice. Acute leptomeningitis (arrow) characterized by neutrophil and macrophage infiltration and fibrin deposition was observed in infected mice of both strains (200X). (B) Cerebrum from the C57BL/6 stat1^{-/-} strain presented with mild acute leptomeningitis (arrow) characterized by neutrophil and macrophage infiltration, which was observed in infected mice of both strains (100X). (C) Nasal turbinate from the C57BL/6 stat1^{-/-} strain presented with fibrinopurulent exudate (arrow) adherent to non-ulcerated respiratory epithelium in infected mouse (200X). (D) Nasal turbinate from the C57BL/6 stat1^{-/-} strain presented with fibrinopurulent rhinitis with inflammatory cells extending throughout the respiratory submucosa. Fibrinopurulent exudate (circled E) occludes the lumen of much of nasal cavity (200X). Pictures are typical results from experiments where N=7.
Figure 4

Protection of single and double MVA vaccinated male and female stat1−/− mice following MPXV infection

(A) Survival of C57BL/6 stat1−/− mice following a primary MVA vaccination at 56 days before MPXV challenge (d-56), or following a primary vaccination with a booster vaccination at 28 days before infection (d-56, d-28). (B) Weight-change in vaccinated and infected animals (N= 21, 7, 9, 19, and 8 for stat1 MVA d-56, d-28; stat1 NI NT; stat1 placebo; stat1 MVA d-56; and B6 MVA d-56, d-28 respectively).

(C and D) Infected and non-infected CD8+ and CD4+ intracellular IFN-γ levels from blood taken 7 days before infection. (E and F) Antibody responses at day -30 and day -7 following the primary MVA vaccination and following a booster vaccination. (NI indicates not infected; NT indicates no treatment; d-56 indicates MVA primary vaccination at 56 days before infection; d-28 indicates MVA booster vaccination at 28 days before infection; pl indicates placebo; MOI indicates Multiplicity of Infection; MOI=0 is mock infected; and B6 indicates C57BL/6 wild-type.

Figure 5

CMX001 and ST-246 partially protect against lethal MPXV challenges

C57BL/6 stat1−/− mice were intranasally infected with 5000 PFU of MPXV and treated with 20 mg/kg of CMX001 on the day of infection followed by every-other-day dosing of 2.5 mg/kg until 14 days p.i. Or, C57BL/6 stat1−/− mice were treated with 100mg/kg of ST-246 daily for 10 days starting on the day of infection. Survival curves and weight changes are shown (A and B, respectively). Vehicle (veh) mice received saline gavages according to the CMX001 dosing regimen or according to the
Figure 6

Anti-orthopoxvirus serum neutralization in mice treated with CMX001 compared to those treated with ST-246

Serum from 28 day p.i. mice was used to determine the 50% serum neutralization values of VACV infected BSC-1 cells. The dashed line indicates the 50% neutralization value.

Table 1. Disease resistance of 4-8 week old immunocompetent murine strains infected with MPXV

<table>
<thead>
<tr>
<th>Strain</th>
<th>Dose (PFU)</th>
<th>Route*</th>
<th>Day of Death Post Infection (% mortality)</th>
<th>Seroconversion</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCID</td>
<td>275</td>
<td>IN</td>
<td>16.8±0.8 (100) N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>SCID</td>
<td>27.5</td>
<td>IN</td>
<td>31±11.3 (40) N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>DBA</td>
<td>5X10⁴</td>
<td>FP/IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>A/Ncr</td>
<td>5X10⁴</td>
<td>FP/IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>C3HeJ</td>
<td>5X10⁴</td>
<td>FP/IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>BALB/c</td>
<td>990</td>
<td>IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>IFNγR⁻/⁻</td>
<td>990</td>
<td>IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>Type 1 IFN⁻/⁻</td>
<td>6X10⁴</td>
<td>FP</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>5X10⁴</td>
<td>FP/IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>C57BL/6 stat1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>470</td>
<td>IN</td>
<td>9.3±0.7 (90)</td>
<td>+</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----</td>
<td>----</td>
<td>-------------</td>
<td>---</td>
</tr>
<tr>
<td>129</td>
<td>5X10&lt;sup&gt;4&lt;/sup&gt;</td>
<td>FP/IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>129 stat1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>470</td>
<td>IN</td>
<td>Survive</td>
<td>+</td>
</tr>
<tr>
<td>129 stat1&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>4700</td>
<td>IN</td>
<td>10 (40)</td>
<td>+</td>
</tr>
</tbody>
</table>

*IN: Intranasal; FP: Footpad injection

Table 2 Tissue necropsy report from MPXV infected C57BL/6 stat1<sup>−/−</sup> mice.
Table 2

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Diagnosis</th>
<th>Severity</th>
<th>Infected</th>
<th>NI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>Number Examined</td>
<td>7</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ventriculitis, acute</td>
<td>Minimal</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leptomeningitis, acute</td>
<td>Mild</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>Number Examined</td>
<td>7</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proteinosis, tubular</td>
<td>Minimal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Number Examined</td>
<td>7</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematopoiesis, extramedullary</td>
<td>Minimal</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammation, subacute</td>
<td>Minimal</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>Number Examined</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematopoiesis, extramedullary</td>
<td>Minimal</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Lung with bronchi</td>
<td>NumberExamined</td>
<td>7</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inflammation, subacute</td>
<td>Mild</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Downloaded from http://jvi.asm.org on October 28, 2017 by guest
| Tissue                  | Number Examined | NSML | Degeneration, cortical | Minimal | Thyroid         | Number Examined | NSML | Inflammation, subacute | Mild | Leptomeningitis, acute | Mild | Larynx          | Number Examined | NSML | Inflammation, lymphoplasmacytic | Mild | Heart          | Number Examined | NSML | Hemosiderosis, valvular | Minimal | Optic nerve | Number Examined | NSML | Leptomeningitis, acute | Mild |
|------------------------|----------------|------|------------------------|---------|----------------|----------------|------|------------------------|-------|------------------------|-------|----------------|----------------|------|------------------------|-------|----------------|----------------|------|------------------------|-------|
| Adrenal gland          | 7              | 2    |                        |         |                 |                |      |                        |       |                        |       | Thyroid         | 7              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | thyroid         | 7              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Larynx          | 7              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Larynx          | 7              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Larynx          | 7              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |

| Adrenal gland          | 7              | 2    |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |
|                        |                |      |                        |         |                 |                |      |                        |       |                        |       | Optic nerve | 5              | 2    |                        |       |                |                |      |                        |       |
NSML (no significant microscopic lesions) reported in: adrenal gland, aorta, cecum, colon, duodenum, esophagus, eye, gall bladder, Harderian gland, heart, ileum, jejunum, kidney, lymph node (mesenteric), mammary gland, optic nerve, pancreas, parathyroid, prostate, rectum, salivary gland, skeletal muscle, tongue, urinary bladder, penis, seminal vesicle, skin, skeletal muscle, spinal cord, stomach, testes, thyroid, tongue, trachea, urinary bladder, uterus with cervix, and vagina.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Number Examined</th>
<th>NSML</th>
<th>Hyperplasia, myeloid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow, sternum</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate</td>
<td>2</td>
</tr>
<tr>
<td>Bone marrow, femur</td>
<td>7</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate</td>
<td>5</td>
</tr>
<tr>
<td>Nasal cavity</td>
<td>7</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe</td>
<td>1</td>
</tr>
<tr>
<td>Thymus</td>
<td>7</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe</td>
<td>3</td>
</tr>
<tr>
<td>Ovary</td>
<td>7</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inflammation, acute</td>
<td>Moderate</td>
</tr>
<tr>
<td>Oviduct</td>
<td>7</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NSML</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inflammation, acute</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
Fig 1

C57BL/6 stat1-/- Female

A

C57BL/6 stat1-/- Male

C

B

D

on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from
Fig 2
Fig 3
Fig 4
Fig 6